Equibles does not estimate personal net worth.
Get an email with a short summary when Travere Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get TVTX alertsThe proxy statement of Travere Therapeutics, Inc. reports total compensation of $2,261,751 for Peter Heerma in fiscal 2025, including a base salary of $527,917. Disclosed compensation is on record for 7 fiscal years. Peter Heerma has spoken on 2 earnings calls and 2 other investor events across 1 company, most recently for Travere Therapeutics, Inc. on August 4, 2026. Travere Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Travere Therapeutics, Inc. includes Bradley Campbell (CEO and Board Member), Bradley L. Campbell (CEO and Board Member), Christopher Cline (CFO) and 7 others.
“Before discussing our commercial performance, I want to recognize the extraordinary work of our commercial organization and colleagues across Travere. Following our FSGS approval in April, our teams have executed with urgency, focus, and discipline while continuing to serve the IGA nephropathy patient community.”
“Yeah, I would say overall, there has been overwhelmingly positive feedback from the community.”
“I'm pleased to share that we started the year strongly and set new records with our Phil Spari performance. The first quarter marked the highest demand to date as we received 993 new patient platforms, reflecting continued expansion among new prescribers and deepening utilization across established accounts.”
“We are incredibly excited about today's approval and the opportunity it creates to bring Phil Spari to the FSDS community. From a commercial perspective, this is a highly actionable opportunity, grounded in a patient population that is both clearly defined and actively managed in clinical practice.”
Proxy statement
Start not stated–present
Last confirmed April 6, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Travere Therapeutics, Inc. (TVTX) | Chief Commercial Officer | $527,917 | $2,261,751 |
| 2024 | Travere Therapeutics, Inc. (TVTX) | Chief Commercial Officer | $503,750 | $1,513,360 |
| 2023 | Travere Therapeutics, Inc. (TVTX) | Chief Commercial Officer | $487,167 | $2,003,914 |
| 2022 | Travere Therapeutics, Inc. (TVTX) | Chief Commercial Officer | $453,190 | $2,005,747 |
| 2021 | Travere Therapeutics, Inc. (TVTX) | Chief Commercial Officer | $421,685 | $1,880,976 |
| 2020 | Travere Therapeutics, Inc. (TVTX) | Chief Commercial Officer | $407,667 | $1,532,290 |
| 2019 | Travere Therapeutics, Inc. (TVTX) | Chief Commercial Officer | $100,000 | $1,325,278 |
